Skip to main content
SpringerLink
Log in

Preclinical Evaluation of ADCs Delivering Highly Potent Pyrrolobenzodiazepine (PBD) Dimers

  • Chapter
  • First Online:
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

The pyrrolobenzodiazepines (PBDs) are tricyclic natural products that exert their biological activity by binding and covalently bonding in the minor groove of DNA. An important development in the history of the PBDs was the synthesis of nonnatural PBD dimers that have the ability to form highly cytotoxic DNA cross-links. Rational structural modification can produce PBD dimers with exquisite potency making them ideal candidates for the ‘warhead’ component of antibody drug conjugates. Two different sites on PBD dimers have been utilised to attach linkers, N10 and C2, and antibody PBD conjugates (APCs) of both types have shown impressive in vitro and in vivo activity against both haematological malignancies and solid tumours. Several APCs including vadastuximab talirine and rovalpituzumab tesirine have progressed into early phase clinical trials.

ADCs delivering PBD dimer payloads represent a novel mode of action in the ADC area. An important feature of the highly cytotoxic DNA interstrand cross-links produced by the PBD dimers is their persistence in cells. This contributes to their potency and also to their ability to affect slowly proliferating target cells, including cancer stem cells. The PBD dimers are a highly flexible platform with many advantages over existing payloads. These include the ability to target low copy number antigens and to exploit low drug-antibody ratios due to the high warhead potency. APCs are active in tumour types inherently resistant to other warhead classes and against multidrug-resistant tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, Gregson SJ, Thurston DE, Sausville EA (2004) SJG-136 (NSC 694501) a novel rationally designed DNA minor groove interstrand crosslinking agent with potent and broad spectrum antitumor activity. Part 2: efficacy evaluations. Cancer Res 64:6700–6706

    Article  CAS  PubMed  Google Scholar 

  • Antonow D, Thurston DE (2011) Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs). Chem Rev 111:2185–2164

    Article  Google Scholar 

  • Antonow D, Kaliszczak M, Kang G-D et al (2010) Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepines (PBD) antitumour agents. J Med Chem 53:2927–2941

    Article  CAS  PubMed  Google Scholar 

  • Arnould S, Spanswick VJ, Macpherson JS, Hartley JA, Thurston DE, Jodrell DI, Guichard SM (2006) Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. Mol Cancer Ther 5:1602–1609

    Article  CAS  PubMed  Google Scholar 

  • Bose DS, Thompson AS, Ching J et al (1992) Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc 114:4939–4941

    Article  CAS  Google Scholar 

  • Clingen PH, De Silva IU, McHugh PJ et al (2005) The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucl Acids Res 33:3283–3291

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CE, Levy J-N, Tiberghien A, Masterson LA, Barry C, D’Hooge F, Marafioti T, Parren PW, Williams DG, Howard PW, van Berkel P, Hartley JA (2016) ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther 15:2709–2721

    Article  PubMed  Google Scholar 

  • Gregson SJ, Howard PW, Hartley JA et al (2001) Design synthesis and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 44:737–748

    Article  CAS  PubMed  Google Scholar 

  • Gregson SJ, Howard PW, Gullick DR et al (2004) Linker length modulates DNA cross-linking reactivity and cytotoxic potency for ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. J Med Chem 47:1161–1174

    Article  CAS  PubMed  Google Scholar 

  • Guichard SM, Macpherson JS, Thurston DE, Jodrell DI (2005) Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. Eur J Cancer 41:1811–1818

    Article  CAS  PubMed  Google Scholar 

  • Harper JW, Lloyd C, Mao S, Lin X, Dimansi N, Howard PW, O’Connor E, Farkas D, Barton C, Smith J, Zhong H, Chen T, Hindrichs MJ, Ribelatto M, Yu Z-Q, Spitz S, Pierce A, Lai D, Hurt E, van Vlerken-Ysla L, Sanjoo J, Miller K, McCullough K, Kannan P, Thompson S, Mahadevia P, Martin CJ, Hollingsworth R, Kamal A (2015) A novel antibody-drug conjugate that induces long-term tumor regression and anticancer stem cell activity. In: Proceedings of the annual meeting of the American Association for Cancer Research, vol 56, Abst 948

    Google Scholar 

  • Hartley JA (2011) The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 20:733–744

    Article  CAS  PubMed  Google Scholar 

  • Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski J, Sausville EA, Gregson SJ, Howard PW, Thurston DE (2004) SJG-136 (NSC 694501) a novel rationally designed DNA minor groove interstrand crosslinking agent with potent and broad spectrum antitumor activity. Part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 64:6693–6699

    Article  CAS  PubMed  Google Scholar 

  • Hartley JA, Hamaguchi A, Coffils M, Martin C, Suggitt M, Chen Z, Gregson SJ, Masterson LA, Tiberghien AC, Hartley JM, Pepper CJ, Lin TT, Fegan C, Thurston DE, Howard PH (2010) SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer pro-drug that cross-links DNA and exerts highly potent antitumor activity. Cancer Res 70:6849–6858

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hartley JA, Hamaguchi A, Suggitt M, Gregson SJ, Thurston DE, Howard PW (2012) DNA interstrand cross-linking and in vivo antitumour activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. Investig New Drugs 30:950–958

    Article  CAS  Google Scholar 

  • Hartley JA, Masterson LA, Gregson SJ, Cailleau T, Ezeadi E, Levy J-N, Kemp G, Tiberghien A, Dunny E, Bulow C, D’Hooge F, Adams L, Williams DG, Boyle W, Short J, van Berkel P, Hoeard PW (2013) Pyrrolobenzodiazepine (PBD) dimers – potent next generation warheads in antibody drug conjugates (ADCs) targeted at both solid and haematological tumors. In: Proceedings of the annual meeting of the American Association for Cancer Research, vol 54, Abst 2856

    Google Scholar 

  • Hertzberg RP, Hecht SM, Reynolds VL et al (1986) DNA sequence specificity of the pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotics. Methidiumpropyl-EDTA-iron(II) footprinting analysis of DNA binding sites for anthramycin and related drugs. Biochemistry 25:1249–1258

    Article  CAS  PubMed  Google Scholar 

  • Howard PH, Chen Z, Gregson SJ et al (2009) Synthesis of a novel C2/C2’-aryl-substituted pyrrolo[2,1-c]-[1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. Bioorg Med Chem Let 19:6463–6466

    Article  CAS  Google Scholar 

  • Hurley LH, Reck T, Thurston DE et al (1988) Pyrrolo[1,4]benzodiazepine antitumour antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chem Res Toxicol 1:258–268

    Article  CAS  PubMed  Google Scholar 

  • Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law C-L, Senter PD (2013) A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation. Bioconjug Chem 24:1256–1263

    Article  CAS  PubMed  Google Scholar 

  • Kadia TM, Faderl S, Estrov Z et al. (2009) Final results of a phase I and pharmacokinetic study of SJG-136 administered on a daily ×5 schedule. J Clin Oncol 27 (suppl; abstr e13506)

    Google Scholar 

  • Korman S, Tendler MD (1965) Clinical investigations of cancer chemotherapeutic agents for neoplastic disease. J New Drugs 5:275–285

    Article  CAS  PubMed  Google Scholar 

  • Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone IJ, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer DW, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA (2013) SGN-CD33A: a novel CD33-targeting antibody drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122(8):1455–1463

    Article  PubMed  Google Scholar 

  • Leimgruber W, Stefanovic V, Shenker F et al (1965) Isolation and characterization of anthramycin, a new antitumour antibiotic. J Am Chem Soc 87:5791–5793

    Article  CAS  PubMed  Google Scholar 

  • Li F, Emmerton KK, Jonas M, Zhang X, Law C-L (2015) Characterization of ADC bystander killing in admixed tumor models. In: Proceedings of the annual meeting of the American Association for Cancer Research, vol 56, Abst 5507

    Google Scholar 

  • Lubeski C, Kemp GC, von Bulow CL, Howard PW, Hartley JA, Douville T, Wellbrock J, Fiedler W, Trombetta S, Gedrich R, Hadari Y, Mandel-Bausch EM (2015) KTN0182A, and anti-KIT pyrrolobenzodiazepine (PBD)-containing antibody drug conjugate (ADC) demonstrates potent antitumor activity in vitro and in vivo against a broad range of tumor types. In: Proceedings of the 11th annual PEGS – The essential protein engineering summit, Boston, 4–8 May

    Google Scholar 

  • Mao S, Flemming R, Bezabeth B, Dimansi N, Toader D, Cailleau T, Howard PW, Gao C, Hollingsworth R, Kamal A, Harper J (2015) Antibody-drug conjugates (ADCs) with tubulysin and PBD warheads maintain potent in vitro cytotoxicity against multidrug-resistant tumor cells expressing P-glycoprotein (P-gp). In: Proceedings of the annual meeting of the American Association for Cancer Research, vol 56, Abst 3601

    Google Scholar 

  • Osawa T, Davies D, Hartley JA (2011) Mechanism of cell death resulting from DNA interstrand cross-linking in mammalian cells. Cell Death Dis 2:e187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pepper CJ, Hambly RM, Fegan CD et al (2004) The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Cancer Res 64:6750–6755

    Article  CAS  PubMed  Google Scholar 

  • Pepper C, Lowe H, Fegan C et al (2007) Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove cross-linking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. Br J Cancer 97:253–259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao C-Y, Hartley JA, Berlin JD, Rothenberg ML (2011) Phase I, pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res 17:3794–3802

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rudin CM, Pietanza C, Bauer TM, Ready NE, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR, for the SCRX16-001 investigators (2017) Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase I study. Lancet Oncol 18:42–51

    Google Scholar 

  • Sandall SL, McCormick RS, Anderson M, Nesterova A, Jonas M, Miyamoto JB, Stone IJ, Zeng W, Law C-L, Lewis TS (2014) SGN-CD70A, a novel and highly potent anti-CD70 ADC, activates single and double strand DNA damage response and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). In: Proceedings of the annual meeting of the American Association for Cancer Research, vol 55, Abst 2647

    Google Scholar 

  • Sandall SL, McCormick RS, Miyamoto JB, Biechele T, Law C-L, Lewis TS (2015) SGN-CD70A, a pyrrolobenzodiazepine (PBD) dimer linked ADC, mediates DNA damage pathway activation and G2 cell cycle arrest leading to cell death. Proceedings of the annual meeting of the American Association for Cancer Research, vol 56, Abst 946

    Google Scholar 

  • Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williamd SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ (2015) A DLL3-targetted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7(302):302ra136

    Article  PubMed  PubMed Central  Google Scholar 

  • Smellie M, Kelland LR, Thurston DE, Souhami RL, Hartley JA (1994) Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor-groove cross-linking agents. Br J Cancer 70:48–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smellie M, Bose DS, Thompson AS, Jenkins TC, Hartley JA, Thurston DE (2003) Sequence selective recognition of duplex DNA through covalent interstrand crosslinking: kinetic and molecular modelling studies with pyrrolobenzodiazepine (PBD) dimers. Biochemistry 42:8232–8239

    Article  CAS  PubMed  Google Scholar 

  • Stein EM, Stein A, Walter RB, Fathi AT, Lancet JE, Kovacsovics TJ, Advani AS, DeAngelo DJ, O’Meara MM, Zhao B, Kennedy DA, Erba HP (2014) Interim analysis of a phase I trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML). In: Proceedings American society haematology annual meeting, Abstract 643

    Google Scholar 

  • Sutherland M, Yu C, Anderson M, Emmerton K, Zeng W, O’Meara M, Kennedy D, Ryan M, Benjamin D (2014) SGN-CD33A in combination with cytarabine or hypomethylating agents demonstrate enhanced anti-leukemic activity in preclinical models of AML. In: Proceedings American society haematology annual meeting, abstract 3739

    Google Scholar 

  • VanBrunt MP, Shanebeck K, Caldwell Z, Johnson J, Thompson P, Martin T, Dong H, Li G, Xu H, D’Hooge F, Masterson LA, Bariola P, Tiberghien A, Ezeadi E, Williams DG, Hartley JA, Howard PW, Grabstein KH, Bowen MA, Marelli M (2015) Genetically encoded azide containing amino acid in mammalian cells enables site-specific antibody-drug conjugates using click cycloaddition chemistry. Bioconjug Chem 26:2249–2260

    Article  CAS  PubMed  Google Scholar 

  • Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell DI, Hochhauser D, Hartley JA (2013) γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from two phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res 19:721–730

    Article  CAS  PubMed  Google Scholar 

  • Zammarchi F, Williams DG, Havenith K, Adams L, D’Hooge F, Howard PW, Hartley JA and van Berkel P (2015) Pre-clinical activity of hLL2-PBD, a novel anti-CD22 antibody-pyrrolobenzodiazepine (PBD) conjugate in models of non-Hodgkin lymphoma. In: Proceedings of the annual meeting of the American Association for Cancer Research, vol 56, Abst 637

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCL Cancer Institute, London, UK

    John A. Hartley

Authors
  1. John A. Hartley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John A. Hartley .

Editor information

Editors and Affiliations

  1. NBE-Therapeutics Ltd., Basel, Switzerland

    Ulf Grawunder

  2. Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

    Stefan Barth

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Hartley, J.A. (2017). Preclinical Evaluation of ADCs Delivering Highly Potent Pyrrolobenzodiazepine (PBD) Dimers. In: Grawunder, U., Barth, S. (eds) Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. Milestones in Drug Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-46877-8_2

Download citation

Publish with us

Policies and ethics

Search

Navigation